Cochrane · systematic review · CD011306
Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids
Ahmad, S, Kew, KM, Normansell, R · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 1 · 14.3%Moderate 6 · 85.7%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Stopping LABA compared with continuing use of LABA+ICS for adults with well‐controlled asthma
Population: adults with asthma well controlled on LABA and ICS
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Exacerbation: systemic corticosteroids 17 weeks Stopping LABA vs continuing use of LABA+ICS | OR 1.74 [0.83, 3.65] | 4 studies · 1257 participants | Moderate |
Asthma control: ACQ 17 weeks Stopping LABA vs continuing use of LABA+ICS | no estimate extracted | 3 studies · 645 participants | Moderate Downgraded: imprecision, publication bias |
Serious adverse events 17 weeks Stopping LABA vs continuing use of LABA+ICS | OR 0.82 [0.28, 2.42] | 5 studies · 1342 participants | Moderate Downgraded: imprecision, publication bias |
Asthma‐related quality of life 12 weeks Stopping LABA vs continuing use of LABA+ICS | no estimate extracted | 2 studies · 359 participants | Moderate Downgraded: imprecision, publication bias |
Exacerbation: hospital 17 weeks Stopping LABA vs continuing use of LABA+ICS | no estimate extracted | 5 studies · 1342 participants | Low Downgraded: imprecision, publication bias |
Adverse events (all) Stopping LABA vs continuing use of LABA+ICS | OR 0.83 [0.66, 1.05] | 5 studies · 1339 participants | Moderate Downgraded: imprecision, publication bias |
Withdrawal (all) Stopping LABA vs continuing use of LABA+ICS | OR 1.95 [1.47, 2.58] | 5 studies · 1352 participants | Moderate Downgraded: imprecision, publication bias |